Evidence map›Paper›PMID 37344376›Full record

ArticleRisk analysis : an official publication of the Society for Risk Analysis2024

Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.

Dominika A Kalkowska, Eric Wiesen, Steven G F Wassilak, Cara C Burns, Mark A Pallansch, Kamran Badizadegan, Kimberly M Thompson

Abstract read
In one paragraph

Article in Risk analysis : an official publication of the Society for Risk Analysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.Medical decision making : an international journal of the Society for Medical Decision Making
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dominika A KalkowskaKid Risk, Inc., Orlando, Florida, USA.
Eric WiesenGlobal Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Steven G F WassilakGlobal Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Cara C BurnsDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mark A PallanschNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-1015-4818
Kamran BadizadeganKid Risk, Inc., Orlando, Florida, USA.ORCID 0000-0003-4900-9455
Kimberly M ThompsonKid Risk, Inc., Orlando, Florida, USA.ORCID 0000-0002-0849-9147

Funding

CDC HHS NU2RGH001915-02-00Intramural CDC HHS NU2RGH001915
6 · The paper itself

Abstract

In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak response. Since then, paralytic polio cases caused by type 2 vaccine-derived polioviruses now exceed 3,000 cases reported by 39 countries. In 2022 (as of April 25, 2023), 20 countries reported detection of cases and nine other countries reported environmental surveillance detection, but no reported cases. Recent development of a genetically modified novel type 2 OPV (nOPV2) may help curb the generation of neurovirulent vaccine-derived strains; its use since 2021 under Emergency Use Listing is limited to outbreak response activities. Prior modeling studies showed that the expected trajectory for global type 2 viruses does not appear headed toward eradication, even with the best possible properties of nOPV2 assuming current outbreak response performance. Continued persistence of type 2 poliovirus transmission exposes the world to the risks of potentially high-consequence events such as the importation of virus into high-transmission areas of India or Bangladesh. Building on prior polio endgame modeling and assuming current national and GPEI outbreak response performance, we show no probability of successfully eradicating type 2 polioviruses in the near term regardless of vaccine choice. We also demonstrate the possible worst-case scenarios could result in rapid expansion of paralytic cases and preclude the goal of permanently ending all cases of poliomyelitis in the foreseeable future. Avoiding such catastrophic scenarios will depend on the development of strategies that raise population immunity to type 2 polioviruses.

Indexed as

PoliomyelitisPoliovirusBangladeshDisease OutbreaksGlobal HealthHumansPoliovirus Vaccine, OralPoliovirus Vaccine, Oraldynamic modelingeradicationinterdependent risksoral poliovirus vaccinepolio

Identifiers

PMID37344376
PMCPMC10733542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.